Breast care | |
HER2 Dimerization Inhibitor Pertuzumab – Mode of Action and Clinical Data in Breast Cancer | |
Tanja Fehm1  Nadia Harbeck1  Norbert Marschner1  Oleg Gluz1  Matthias W. Beckmann1  Iris Schrader1  Volkmar Müller1  Andreas Schneeweiss1  Georg Heinrich1  Achim Rody1  Michael Untch1  Christian Jackisch1  | |
[1] aBrustzentrum, Frauenklinik, Universität München (LMU), Klinikum Offenbach, Germany | |
关键词: HER2-positive; Dual inhibition; Breast cancer; metastatic; Pertuzumab; Trastuzumab; | |
DOI : 10.1159/000346837 | |
学科分类:泌尿医学 | |
来源: S Karger AG | |
【 摘 要 】
The humanized monoclonal antibody pertuzumab prevents the dimerization of HER2 with other HER receptors, in particular the pairing of the most potent signaling heterodimer HER2/HER3, thus providing a potent strategy for dual HER2 inhibition. It binds to the extracellular domain of HER2 at a different epitope than trastuzumab. Pertuzumab and trastuzumab act in a complementary fashion and provide a more complete blockade of HER2-mediated signal transduction than either agent alone. Phase II studies demonstrated that pertuzumab was generally well tolerated as a single agent or in combination with trastuzumab and/or cytotoxic agents, and implied an improved clinical efficacy of the combination of pertuzumab and trastuzumab in early and advanced HER2-positive breast cancer. Results of the pivotal phase III study CLEOPATRA in patients with HER2-positive metastatic breast cancer demonstrated that the addition of pertuzumab to first-line combination therapy with docetaxel and trastuzumab significantly prolonged progression-free and overall survival without increasing cardiac toxicity. Currently, the combination of both antibodies is being explored in the palliative setting as well as in the treatment of early HER2-positive breast cancer. Dual HER2 inhibition with the HER2 dimerization inhibitor pertuzumab and trastuzumab may change clinical practice in HER2-positive first-line metastatic breast cancer treatment.
【 授权许可】
Unknown
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO201911300344944ZK.pdf | 464KB | download |